AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14753103 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group 1 (10 teeth): Acid-etched and sealed enamel area with surrounding sound enamel subjected to demineralization.
Number of subjects: 28
Study 14753103 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group 2 (13 teeth): Demineralized enamel window that was subsequently etched and sealed.
Number of subjects: 28
Study 14753103 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 teeth): Baseline reference for test procedures.
Number of subjects: 28
Study 11524323 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream and inhaled air and oxygen
Number of subjects: 40
Study 11524323 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (N2O) with placebo cream and inhaled 70% N2O in oxygen
Number of subjects: 40
Study 11524323 — intervention group
Group type: COMPARATOR
Intervention: N2O
Number of subjects: 40
Study 9236570 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in hospitals with higher perioperative mortality rates than trials
Number of subjects: 0
Study 9236570 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in patients with comorbidity exceeding trial criteria
Number of subjects: 0
Study 8515137 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly external microwave hyperthermia treatments combined with radiation therapy
Number of subjects: 41
Study 8515137 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly external microwave hyperthermia treatments combined with radiation therapy
Number of subjects: 41
Study 8515137 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly hyperthermia
Number of subjects: 41
Study 8515137 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly hyperthermia
Number of subjects: 41
Study 8515137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 41
Study 3822503 — intervention group
Group type: EXPERIMENTAL
Intervention: Low osmolar (LO) compound
Number of subjects: 162
Study 3822503 — intervention group
Group type: EXPERIMENTAL
Intervention: High osmolar (HO) compound
Number of subjects: 162
Study 3822503 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo) (PL)
Number of subjects: 162
Study 31980143 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant capecitabine for six months at the usual dose
Number of subjects: 450
Study 31980143 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 450
Study 31586838 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated ketamine-assisted ECT (group RK), ketamine at the dose of 0.3 mg/kg for each ECT treatment
Number of subjects: 134
Study 31586838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent ketamine-assisted ECT (group IK), ketamine once a week during ECT course
Number of subjects: 134
Study 31586838 — intervention group
Group type: COMPARATOR
Intervention: Routine ECT group (group E)
Number of subjects: 134
Study 26973025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous progesterone
Number of subjects: 575
Study 26973025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 575
Study 25966929 — intervention group
Group type: EXPERIMENTAL
Intervention: APC8015-2 (an investigational form of sipuleucel-T)
Number of subjects: 1
Study 25966929 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial sipuleucel-T
Number of subjects: 1
Study 24072967 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (n = 10)
Number of subjects: 20
Study 24072967 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 20
Study 21127896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling vest with PCM at 24°C melting temperature
Number of subjects: 3
Study 21127896 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling vest with PCM at 28°C melting temperature
Number of subjects: 3
Study 21127896 — intervention group
Group type: COMPARATOR
Intervention: Control group without vest
Number of subjects: 3
Study 19577876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DMED)
Number of subjects: 3
Study 17952277 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior lumbar spinal fusion with pedicle screws (PLF)
Number of subjects: 60
Study 17952277 — intervention group
Group type: COMPARATOR
Intervention: Posterior lumbar interbody fusion with pedicle screws (PLIF)
Number of subjects: 60
Study 15292035 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose ingestion
Number of subjects: 20
Study 15292035 — intervention group
Group type: COMPARATOR
Intervention: Control (no glucose ingestion)
Number of subjects: 20
Study 11720830 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg daily for 3 years
Number of subjects: 73
Study 11720830 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 9740462 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 600 mg oral mifepristone and 50 mg/m2 methotrexate
Number of subjects: 50
Study 9740462 — intervention group
Group type: COMPARATOR
Intervention: 50 mg/m2 methotrexate alone
Number of subjects: 50
Study 7810153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 24
Study 3380557 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion blockade with bupivacaine
Number of subjects: 28
Study 3380557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous regional sympathetic blockade with guanethidine
Number of subjects: 28
Study 3380557 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) injection with physiologic saline
Number of subjects: 28
Study 3380557 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine intramuscularly
Number of subjects: 28
Study 30008242 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 48
Study 30008242 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk Walking (BW)
Number of subjects: 48
Study 27564555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 296
Study 27564555 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron 0.075 mg
Number of subjects: 296
Study 27564555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg (TT genotype patients)
Number of subjects: 296
Study 27564555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg (non-TT genotype patients)
Number of subjects: 296
Study 27564555 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron 0.075 mg (TT genotype patients)
Number of subjects: 296
Study 25286965 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine mixed with dexamethasone 2.5 mg
Number of subjects: 30
Study 25286965 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% lidocaine mixed with dexamethasone 2.5 mg
Number of subjects: 30
Study 25286965 — intervention group
Group type: COMPARATOR
Intervention: Both groups (1% lidocaine and 0.125% lidocaine)
Number of subjects: 30
Study 23154578 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d lutein (A+L)
Number of subjects: 65
Study 23154578 — intervention group
Group type: COMPARATOR
Intervention: Placebo (A+P)
Number of subjects: 65
Study 21632713 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep after vaccination
Number of subjects: 27
Study 21632713 — intervention group
Group type: COMPARATOR
Intervention: Wakefulness after vaccination
Number of subjects: 27
Study 19493418 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S1 (propofol target plasma concentration of 4.0 microg/ml)
Number of subjects: 90
Study 19493418 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S2 (initial target plasma concentration of 2.0 microg/ml raised to 4.0 microg/ml after 3 minutes)
Number of subjects: 90
Study 19493418 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S3 (three-step TCI starting from 2.0 microg/ml to 4.0 microg/ml)
Number of subjects: 90
Study 19493418 — intervention group
Group type: COMPARATOR
Intervention: Group S1
Number of subjects: 90
Study 19493418 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups after intubation
Number of subjects: 90
Study 19493418 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 90
Study 16686565 — intervention group
Group type: EXPERIMENTAL
Intervention: Step aerobics training (50 minutes per day, 3 days per week for 10 weeks, at 60-80% of heart rate reserve)
Number of subjects: 118
Study 16686565 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 118
Study 16686565 — intervention group
Group type: EXPERIMENTAL
Intervention: Step aerobics training
Number of subjects: 118
Study 15225166 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (5 million units daily for 2 months)
Number of subjects: 28
Study 15225166 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical series of 16 untreated patients)
Number of subjects: 28
Study 11426093 — intervention group
Group type: EXPERIMENTAL
Intervention: 5g intravenous bolus of MgSO4
Number of subjects: 14
Study 11426093 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 14
Study 9231547 — intervention group
Group type: COMPARATOR
Intervention: Regular heparin (Group I) in conventional dose as continuous infusion for 5 days
Number of subjects: 40
Study 9231547 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose low molecular weight heparin (LMWH) (Group II), 3500 units subcutaneous twice daily for a period of 5 days
Number of subjects: 40
Study 9231547 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group II)
Number of subjects: 40
Study 7589598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg given twice daily with chemotherapy
Number of subjects: 35
Study 7589598 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 35
Study 2141109 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (3 g orally daily)
Number of subjects: 18
Study 2141109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 114198 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day regimen of triple tetracycline (Deteclo), one tablet twice daily for 21 days
Number of subjects: 143
Study 114198 — intervention group
Group type: COMPARATOR
Intervention: 7-day regimen of triple tetracycline (Deteclo), one tablet twice daily for 7 days
Number of subjects: 143
Study 114198 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-day regimen of triple tetracycline (Deteclo)
Number of subjects: 143
Study 114198 — intervention group
Group type: COMPARATOR
Intervention: 7-day regimen of triple tetracycline (Deteclo)
Number of subjects: 143
Study 30975950 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane (TAP) block
Number of subjects: 50
Study 30975950 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 27988967 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50 mg/day
Number of subjects: 1160
Study 27988967 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 100 mg/day
Number of subjects: 1160
Study 27988967 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 200 mg/day
Number of subjects: 1160
Study 27988967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160
Study 25777347 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (40 mg three times daily)
Number of subjects: 40
Study 25777347 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (cisplatin and vinorelbine) without disulfiram
Number of subjects: 40
Study 24884848 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of a single mandibular midline implant with an overdenture
Number of subjects: 180
Study 24884848 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading of a single mandibular midline implant with an overdenture
Number of subjects: 180
Study 21735533 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA) during primary percutaneous coronary intervention (PPCI)
Number of subjects: 619
Study 21735533 — intervention group
Group type: COMPARATOR
Intervention: Conventional PPCI without thrombus aspiration
Number of subjects: 619
Study 20196703 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential exposure to color conditions (same, mixed, unique)
Number of subjects: 60
Study 20196703 — intervention group
Group type: EXPERIMENTAL
Intervention: Set 1 and Set 2 exposures
Number of subjects: 60
Study 18045306 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (400 mg/kg once a month)
Number of subjects: 15
Study 18045306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18045306 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 15
Study 16086839 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac solution (Pennsaid)
Number of subjects: 216
Study 16086839 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control solution
Number of subjects: 216
Study 11936244 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Deterioration Scale (GDS) scores between 4 and 6 (n = 21)
Number of subjects: 39
Study 11936244 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Deterioration Scale (GDS)
Number of subjects: 39
Study 11936244 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Deterioration Scale (GDS) score classification
Number of subjects: 39
Study 10547166 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote, intercessory prayer (prayer group)
Number of subjects: 990
Study 10547166 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 990
Study 8705087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydrochlorothiazide
Number of subjects: 12
Study 8705087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral furosemide
Number of subjects: 12
Study 8705087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous furosemide
Number of subjects: 12
Study 8705087 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 12
Study 1719655 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 206
Study 1719655 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70
Number of subjects: 206
Study 1719655 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 206
Study 6667629 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous beclomethasone dipropionate nasal spray (100 micrograms into each nostril twice daily for 14 days)
Number of subjects: 42
Study 6667629 — intervention group
Group type: COMPARATOR
Intervention: Conventional pressurized spray
Number of subjects: 42
Study 30561237 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) inhibitor (tocilizumab)
Number of subjects: 0
Study 30561237 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-13 (IL-13)
Number of subjects: 0
Study 29110681 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 230
Study 29110681 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on treatment with mianserin
Number of subjects: 230
Study 29110681 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on treatment with Imagery Rehearsal Therapy (IRT)
Number of subjects: 230
Study 29110681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mianserin and IRT
Number of subjects: 230
Study 25554997 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention on diet and physical activity for 18 months
Number of subjects: 129
Study 25554997 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed individuals
Number of subjects: 129
Study 23494559 — intervention group
Group type: EXPERIMENTAL
Intervention: JobTIPS employment program (training intervention)
Number of subjects: 22
Study 23494559 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 22
Study 22097195 — intervention group
Group type: EXPERIMENTAL
Intervention: CM comprehensive regimen (intravenous dripping of Chinese herbal preparation, oral administration of Chinese herbal decoction, and point application)
Number of subjects: 50
Study 22097195 — intervention group
Group type: COMPARATOR
Intervention: Single-agent maintenance chemotherapy (pemetrexed, docetaxel, or gemcitabine)
Number of subjects: 50
Study 22097195 — intervention group
Group type: EXPERIMENTAL
Intervention: CM comprehensive regimen (MT)
Number of subjects: 50
Study 22097195 — intervention group
Group type: COMPARATOR
Intervention: Single-agent maintenance chemotherapy (control)
Number of subjects: 50
Study 19705345 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg bid
Number of subjects: 546
Study 19705345 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide up to 320 mg/day
Number of subjects: 546
Study 16622596 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha treatment (6 microg/kg once a week for 8 weeks, then 3 microg/kg/week)
Number of subjects: 40
Study 16622596 — intervention group
Group type: COMPARATOR
Intervention: Observation only (control group)
Number of subjects: 40
Study 15087628 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg ropivacaine
Number of subjects: 120
Study 15087628 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg levobupivacaine
Number of subjects: 120
Study 15087628 — intervention group
Group type: COMPARATOR
Intervention: 100 mg lidocaine
Number of subjects: 120
Study 15087628 — intervention group
Group type: COMPARATOR
Intervention: 5 ml intravenous saline
Number of subjects: 120
Study 11356389 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 28
Study 11356389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 1524689 — intervention group
Group type: EXPERIMENTAL
Intervention: Rembrandt dentifrice
Number of subjects: 18
Study 1524689 — intervention group
Group type: COMPARATOR
Intervention: Crest dentifrice
Number of subjects: 18